Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The 2024 Drugs to Watch, are: 1. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 173

Drugs Therapies Treatment Virus 173

Alta Sciences

MARCH 8, 2024

So much so that the HPAPI market is estimated to reach USD 31.5 billion by 2029. Thousands of HPAPIs are currently in development that promise lower dose requirements, enhanced efficacy, improved patient compliance, and fewer side effects. View the full library of The Altascientist publications.

Compliance 52

Compliance Engineering Regulations Pharmaceuticals 52

Policy Prescription

MARCH 26, 2021

Would you vote for legislation to lower drug prices that would lead to a five percent reduction in pharmaceutical innovation — yet simultaneously create a health system in which all Americans could afford the prescription drugs they need? That’s compared to the one we have now where a quarter of Americans struggle with drug prices.

Drugs 52

Drugs Government Vaccine Pharmaceuticals 52

Vial

MARCH 1, 2024

By geographical region, the global CRO services market in 2023 was dominated by North America. Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market.

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

Agency IQ

FEBRUARY 2, 2024

This means that the medical device frameworks – including the pre-market pathways and evidentiary requirements, as well as post-market quality system frameworks and reporting requirements – are applied to the vast majority of all (CDRH-regulated) IVD products. Are there implications for drug or therapeutic developers?

FDA 40

FDA Regulations Laboratories Production 40

Drug Discovery World

JULY 26, 2024

While the shadow of the pandemic recedes, its effects linger in the form of a market correction and an evolving healthcare landscape. The Democrats’ Inflation Reduction Act (IRA) – particularly its Medicare drug price negotiation provision – is being touted as a win against ‘Big Pharma’s price gouging’.

Science 130

Science Government Biosimilars Marketing 130